Tugba Songul Tat1, Aykut Cilli2. 1. a Department of Internal Medicine, School of Medicine , Akdeniz University , Antalya , Turkey. 2. b Department of Pulmonary Medicine, School of Medicine , Akdeniz University , Antalya , Turkey.
Abstract
INTRODUCTION: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported. METHODS: We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study. RESULTS: After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results. CONCLUSION: Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed.
INTRODUCTION:Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported. METHODS: We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study. RESULTS: After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results. CONCLUSION: Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed.